MEP37108A - Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-yl-metheyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethansulfonate - Google Patents

Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-yl-metheyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethansulfonate

Info

Publication number: MEP37108A
Authority: ME; Montenegro
Prior art keywords: piperazinyl; biphenyl; benzoxazolone; monomethansulfonate; metheyl
Prior art date: 2003-08-18

Application number

MEP-371/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Klaas Zwier

Gerrit Klein

Irene Eijgendaal

Horst-Van Amstel Maria J L Ter

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-18

Filing date

2004-08-18

Publication date

2011-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP37108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-18 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2011-02-10 Publication of MEP37108A publication Critical patent/MEP37108A/xx

Links

ONWKHSGOYGLGPO-UHFFFAOYSA-N methanesulfonic acid;7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3h-1,3-benzoxazol-2-one Chemical compound CS(O)(=O)=O.C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 ONWKHSGOYGLGPO-UHFFFAOYSA-N 0.000 title abstract 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 2
235000010290 biphenyl Nutrition 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 2
229940127557 pharmaceutical product Drugs 0.000 abstract 2
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
-1 compound 7- [4 - ([1,1'-biphenyl] -3-ylmethyl) -1-piperazinyl] -2 (3H) -benzoxazolone monomethanesulfonate Chemical class 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Psychology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicinal Preparation (AREA)

MEP-371/08A 2003-08-18 2004-08-18 Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-yl-metheyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethansulfonate MEP37108A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US49570803P	2003-08-18	2003-08-18
EP03102573		2003-08-18
PCT/EP2004/051816 WO2005016898A2 (en)	2003-08-18	2004-08-18	Stable polymorph of bifeprunox mesilate

Publications (1)

Publication Number	Publication Date
MEP37108A true MEP37108A (en)	2011-02-10

Family

ID=34924088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-371/08A MEP37108A (en)	2003-08-18	2004-08-18	Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-yl-metheyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethansulfonate

Country Status (26)

Country	Link
EP (1)	EP1656358B1 (de)
JP (1)	JP2007502802A (de)
CN (1)	CN100422159C (de)
AR (1)	AR045362A1 (de)
AT (1)	ATE499348T1 (de)
AU (1)	AU2004265104B2 (de)
BR (1)	BRPI0413617A (de)
CA (1)	CA2536149C (de)
DE (1)	DE602004031534D1 (de)
DK (1)	DK1656358T3 (de)
EA (1)	EA008182B1 (de)
ES (1)	ES2361508T3 (de)
IS (1)	IS8279A (de)
ME (1)	MEP37108A (de)
MX (1)	MXPA06001881A (de)
MY (1)	MY139462A (de)
NO (1)	NO20061265L (de)
NZ (1)	NZ545415A (de)
PL (1)	PL1656358T3 (de)
PT (1)	PT1656358E (de)
RS (1)	RS20060113A (de)
SI (1)	SI1656358T1 (de)
TW (1)	TWI336695B (de)
UA (1)	UA85562C2 (de)
WO (1)	WO2005016898A2 (de)
ZA (1)	ZA200601399B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7423040B2 (en) *	2005-02-18	2008-09-09	Irene Eijgendaal	Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
KR20090033871A (ko) *	2006-06-16	2009-04-06	솔베이 파마슈티칼스 비. 브이	비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제
CA2661120A1 (en)	2006-08-31	2008-03-06	Solvay Pharmaceuticals B.V.	Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
WO2011023796A1 (en)	2009-08-31	2011-03-03	Abbott Healthcare Products B.V.	Bifeprunox for treating addiction
US9675101B2 (en)	2013-03-15	2017-06-13	Whirlpool Corporation	High performance adjustable juicer with whole foods feed chute

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3989554B2 (ja) *	1996-03-29	2007-10-10	デユフアー・インターナシヨナル・リサーチ・ベー・ブイ	ピペラジンおよびピペリジン化合物
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
WO1999032115A1 (en) *	1997-12-19	1999-07-01	Advanced Research And Technology Institute, Inc.	Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
AR034206A1 (es) *	2001-02-16	2004-02-04	Solvay Pharm Bv	Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos

2004
- 2004-08-13 AR ARP040102906A patent/AR045362A1/es unknown
- 2004-08-16 TW TW093124532A patent/TWI336695B/zh not_active IP Right Cessation
- 2004-08-16 MY MYPI20043324A patent/MY139462A/en unknown
- 2004-08-18 EA EA200600442A patent/EA008182B1/ru not_active IP Right Cessation
- 2004-08-18 WO PCT/EP2004/051816 patent/WO2005016898A2/en not_active Ceased
- 2004-08-18 ES ES04766517T patent/ES2361508T3/es not_active Expired - Lifetime
- 2004-08-18 CN CNB2004800235660A patent/CN100422159C/zh not_active Expired - Fee Related
- 2004-08-18 RS YUP-2006/0113A patent/RS20060113A/sr unknown
- 2004-08-18 UA UAA200602994A patent/UA85562C2/ru unknown
- 2004-08-18 ME MEP-371/08A patent/MEP37108A/xx unknown
- 2004-08-18 JP JP2006523633A patent/JP2007502802A/ja active Pending
- 2004-08-18 BR BRPI0413617-9A patent/BRPI0413617A/pt not_active IP Right Cessation
- 2004-08-18 AT AT04766517T patent/ATE499348T1/de active
- 2004-08-18 PL PL04766517T patent/PL1656358T3/pl unknown
- 2004-08-18 AU AU2004265104A patent/AU2004265104B2/en not_active Ceased
- 2004-08-18 DE DE602004031534T patent/DE602004031534D1/de not_active Expired - Lifetime
- 2004-08-18 EP EP04766517A patent/EP1656358B1/de not_active Expired - Lifetime
- 2004-08-18 SI SI200431663T patent/SI1656358T1/sl unknown
- 2004-08-18 DK DK04766517.9T patent/DK1656358T3/da active
- 2004-08-18 MX MXPA06001881A patent/MXPA06001881A/es active IP Right Grant
- 2004-08-18 PT PT04766517T patent/PT1656358E/pt unknown
- 2004-08-18 CA CA2536149A patent/CA2536149C/en not_active Expired - Fee Related
- 2004-08-18 NZ NZ545415A patent/NZ545415A/en not_active IP Right Cessation
2006
- 2006-01-31 IS IS8279A patent/IS8279A/is unknown
- 2006-02-16 ZA ZA200601399A patent/ZA200601399B/en unknown
- 2006-03-20 NO NO20061265A patent/NO20061265L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1656358A2 (de)	2006-05-17
MY139462A (en)	2009-10-30
TWI336695B (en)	2011-02-01
NO20061265L (no)	2006-05-09
SI1656358T1 (sl)	2011-06-30
AU2004265104B2 (en)	2009-06-04
CN1835935A (zh)	2006-09-20
DE602004031534D1 (de)	2011-04-07
WO2005016898B1 (en)	2005-05-19
JP2007502802A (ja)	2007-02-15
UA85562C2 (en)	2009-02-10
RS20060113A (sr)	2008-09-29
IS8279A (is)	2006-01-31
EP1656358B1 (de)	2011-02-23
PL1656358T3 (pl)	2011-07-29
NZ545415A (en)	2009-11-27
EA200600442A1 (ru)	2006-08-25
WO2005016898A3 (en)	2005-04-07
CN100422159C (zh)	2008-10-01
ZA200601399B (en)	2007-04-25
CA2536149A1 (en)	2005-02-24
AU2004265104A1 (en)	2005-02-24
ATE499348T1 (de)	2011-03-15
ES2361508T3 (es)	2011-06-17
TW200513462A (en)	2005-04-16
BRPI0413617A (pt)	2006-10-17
CA2536149C (en)	2011-03-22
MXPA06001881A (es)	2006-05-17
PT1656358E (pt)	2011-05-12
AR045362A1 (es)	2005-10-26
DK1656358T3 (da)	2011-05-30
WO2005016898A2 (en)	2005-02-24
EA008182B1 (ru)	2007-04-27

Similar Documents

Publication	Publication Date	Title
WO2003004480A3 (en)	2004-03-25	Substituted piperazine and diazepanes as histamine h3 receptor agonists
SE0402735D0 (sv)	2004-11-09	Novel compounds
ATE378332T1 (de)	2007-11-15	Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon
MEP13408A (en)	2010-06-10	Cdk inhibiting pyrimidines, production thereof and their use as medicaments
MX2008013836A (es)	2008-11-10	Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
MY138352A (en)	2009-05-29	Benzothiazole derivatives
WO2008097538A8 (en)	2008-10-23	Therapeutic agents
NO20080670L (no)	2008-04-01	Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
NO20061151L (no)	2006-03-10	Succinat- og malonatsalt av trans-4-((ir,3s)-6-klor-3-fenylindan-i-yl)-1,2,2-trimetylpiperazin og anvendelsen som et medikament
ES2192264T3 (es)	2003-10-01	Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina.
MXPA04002338A (es)	2004-06-29	Derivados de carbazol y su uso como antagonistas receptores del npy5.
CA2252898A1 (en)	1997-11-13	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
JP2009532504A5 (de)	2010-05-27
DE60329330D1 (de)	2009-10-29	Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
EA200971086A1 (ru)	2010-04-30	Фармацевтические композиции и способ лечения шизофрении
CN102459252A (zh)	2012-05-16	用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶
MA46268A (fr)	2019-07-31	Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
EP1817311A4 (de)	2010-09-15	2,3,4,6-substituierte pyridylderivat-verbindungen als beta-sektretase-inhibitoren zur behandlung von morbus alzheimer
MEP37108A (en)	2011-02-10	Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-yl-metheyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethansulfonate
FR2885129B1 (fr)	2007-06-15	Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
DE602005027677D1 (de)	2011-06-09	1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
DE50312523D1 (de)	2010-04-29	Pharmazeutische wirkstoffkombination sowie deren verwendung
DK1853232T3 (da)	2009-12-14	Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse
BRPI0607214A2 (pt)	2009-08-18	derivados de 2-(4-cianofenilamino) pirimidina inibidores de hiv
AR037711A1 (es)	2004-12-01	Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen